

# INKA HEALTH

## Revolutionizing Precision Oncology with Causal AI and Big Pharma Collaborations



### Highlights of INKA HEALTH

#### Pioneering AI For Personalized Cancer Care

Inka.AI is at the forefront of a global shift in cancer treatment, leveraging cutting-edge **causal AI technology to redefine drug discovery and precision medicine**. With its proprietary **SynoGraph™** platform, Inka.AI transforms vast and complex health data into actionable insights, enabling personalized treatment strategies that drastically improve patient outcomes. By focusing on genomic, proteomic, and multimodal data, Inka.AI not only identifies the “how” but the “why” behind disease mechanisms, paving the way for a future where every cancer treatment is uniquely tailored to the individual.

#### De-Risking Drug Discovery with Precision AI

Using its world-class innovative AI-driven approach, Inka.AI is poised to demonstrate life-changing results for patients, turning months of projected survival into years. Its proprietary and patented **SynoGraph™** platform emulates **precision-medicine clinical trials**, significantly **reducing the time and cost associated with late-stage drug discovery and clinical research**. With unique access to rich Canadian, U.S. and European patient datasets, Inka.AI excels at identifying high-potential drug candidates, optimizing clinical trials, and de-risking pipeline investments for pharmaceutical partners.

#### Proven Partnerships with Pharma Leaders

Inka.AI has established partnerships with some of the world's biggest pharmaceutical companies, including **AstraZeneca Canada**, and global data holders like **Quantify Research** showcasing its proven ability to collaborate with industry giants and deliver transformative solutions in precision medicine.

Inka.AI is positioned as a game-changer in the **\$200 billion global oncology drug market**, with annual R&D expenditures exceeding \$50 billion. By unlocking the untapped potential of the **97% of health data that goes unused**, Inka.AI bridges the gap between cutting-edge science and transformative patient care, solidifying its leadership in the evolution of oncology-focused AI.

### World-Class Executive Team



**Dr. James Orbinski, MD**  
Strategic Advisor

Nobel Peace Prize recipient, humanitarian, scholar, and Officer of the Order of Canada. He is the Founding Director of York University's Dahdaleh Institute for Global Health Research and former International Council President of Médecins Sans Frontières (Doctors Without Borders).



**Dr. Paul Arora, PhD**  
Chief Executive Officer

Epidemiologist and Adjunct Faculty at University of Toronto. Over 50+ scientific publications and expertise in advanced analytics. Co-Founder of Lighthouse Outcomes (acquired) and Inka Health.



**Dr. Stephen Jones, PhD**  
Scientific Advisor

Head of Bioinformatics and Co-Director of the Genome Sciences Centre in Vancouver, and Distinguished Scientist at the BC Cancer Research Institute. He holds the position of Research Chair in Computational Genomics and has authored over 300 scientific publications.



**Dr. Winson Cheung, MD**  
Medical Advisor

Leading GI Oncologist and Clinical Researcher with 15+ years in cancer research, he has published over 300 scientific papers and secured over \$20M in research funding, specializing in health outcomes and real-world evidence generation in oncology.



**Dr. Edward J Mills, PhD**  
Scientific Advisor

A researcher with over 550 peer-reviewed publications in top journals like NEJM, The Lancet, and JAMA, co-founded MTEK Sciences and Redwood Outcomes (both acquired) and is a leading principal investigator of adaptive platform trials and large-scale studies.



**Dr. Kristian Thorlund, PhD**  
Strategic Advisor

Co-founder of Redwood Outcomes, MTEK Sciences (both acquired), and rAire, as well as the founder of Biospark.ai. He is leading biostatistician specializing in Bayesian methods, he is a Clarivate Analytics Highly Cited Researcher, recognized for his impactful contributions to the field.